annamycin

annamycin

Oncology A liposomal anthracycline for treating CAs–eg multiple-drug-resistant tumors–eg, refractory breast CA, refractory/relapsed AML, ALL, blast crisis of CML. See Anthracycline, Liposomes.
References in periodicals archive ?
M2 PHARMA-March 23, 2017-Moleculin awarded orphan drug designation for Annamycin to treat acute myeloid leukemia
Pharmaceutical company Moleculin Biotech Inc (NasdaqCM:MBRX) reported on Wednesday the receipt of Orphan Drug Designation from the US Food and Drug Administration (FDA) for Annamycin.
The company's lead candidate Annamycin, also known as Liposomal Annamycin, is indicated for the treatment of acute myeloid leukemia (AML).
Annamycin is an anthracycline intended for the treatment of relapsed or refractory AML.
M2 EQUITYBITES-March 23, 2017-Moleculin awarded orphan drug designation for Annamycin to treat acute myeloid leukemia
Dermin") to use the latter's supply of Annamycin for its proposed clinical trial.
We look forward to beginning our expanded clinical trials on Annamycin by the first half of 2017.
Many anti-cancer agents such as doxorubicin, daunorubicin, annamycin, vincristine, paclitaxel and cisplatin, camptothecin and 5-fluorouracil derivatives have been successfully encapsulated in liposomes.
And his early work on Annamycin, a drug that we recently in-licensed from M.